Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
Mohammad Naghavi-BehzadMarianne VogsenRasmus Mølgård VesterMaiken Madsen Bjerregaard OlsenHjalte OltmannPoul-Erik BraadJon Thor AsmussenOke GerkeWerner VachKristian KidholmAnnette Raskov KodahlWolfgang WeberMalene Grubbe HildebrandtPublished in: British journal of cancer (2022)
In this single-center, observational study, patients with metastatic breast cancer who were response monitored with FDG-PET/CT alone or in combination with CE-CT had longer overall survival than patients monitored with CE-CT alone. Confirmation of these findings by further, preferably randomised clinical trials is warranted.
Keyphrases
- metastatic breast cancer
- clinical trial
- image quality
- dual energy
- computed tomography
- contrast enhanced
- end stage renal disease
- newly diagnosed
- ejection fraction
- positron emission tomography
- chronic kidney disease
- energy transfer
- prognostic factors
- open label
- free survival
- peritoneal dialysis
- study protocol
- randomized controlled trial
- double blind
- pet ct
- placebo controlled
- quantum dots